Right heart failure laboratory findings

Revision as of 02:00, 19 November 2012 by Rim Halaby (talk | contribs)
Jump to navigation Jump to search

Right heart failure Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating Right heart failure from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Right heart failure laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Google Images

American Roentgen Ray Society Images of Right heart failure laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Right heart failure laboratory findings

CDC on Right heart failure laboratory findings

Right heart failure laboratory findings in the news

Blogs on Right heart failure laboratory findings

Directions to Hospitals Treating Right heart failure

Risk calculators and risk factors for Right heart failure laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Jad Z Al Danaf; Rim Halaby

Overview

Laboratory tests are useless in the diagnosis heart failure, however they are essential in identifying possible precipitating factors of decompensation, assessing severity of the heart failure, monitoring the side effects of medical treatment and some serve as prognostic markers.[1] In addition, in patients with right heart failure, an arterial blood gas can be useful in assessing the degree of hypoxemia. This can in turn be used to guide therapy with oxygen.

Laboratory Tests

Complete Blood count[2]

  • Anemia might trigger decompensation

ESR

  • Low lymphocyte, >7000/µL basal white cell count and ESR>15mm in first hour might indicate worse prognosis
  • To be repeated every 6 months unless needed to be repeated more frequently.

Serum Electrolytes and Creatinine[2]

  • Hypernatremia, increase in serum creatinine and hypokalemia might result from aggressive diuretic therapy.
  • Hypokalemia and hypomagnesemia as side effects of potassium-losing diuretics
  • Hyperkalemia secondary to renal failure, excessive potassium intake or as a side effect of diuretics (ACR-I, ARB and spironolactone)
  • Target range for K+ should be 4-5 mEq/L
  • To be repeated daily to adjust dose of diuretics and then every 2-3 months in stable patients.

Serum Uric acid

  • Hyperuricemia can be seen in renal failure and secondary to thiazide diuretic use. It is also seen in cardiac cachectic patients.
  • To be repeated every 6 months in stable patients and 3 months in patients on high diuretic doses.

Liver Function tests

  • Elevated ALK phosphatase, liver transaminases and total bilirubin can be secondary to liver congestion.
  • Elevated Gamma-Glutamyltransferase values are sensitive but nonspecific indicators of heart failure.
  • Hypo-albuminemia can be seen in malnutrition or renal dysfunction. It also raises the suspicion of protein losing enteropathy which necessitates checking stool alpha-1 antitrypsin level.
  • To be repeated every 6-12 months in stable patients, during every heart failure decompensatory episode and in pathologic weight loss.

Coagulation tests

  • INR especially during anticoagulant therapy or in setting of hepatic dysfunction-nutmeg liver.

Cardiac Troponins

  • Highly sensitive troponin I (hs-cTnI) servea as outcome predictors with more sensitivity then cardiac Toponin T (cTnT).

Thyroid hormones

  • Must be measured in cases of atrial fibrillation, dilated cardiomyopathy, patient on amiodarone therapy and in patients older than 65 years of age.
  • Blood Glucose level in non-diabetics
  • High Blood glucose level in non-diabetic patients can be secondarily to high diuretic doses such as thiazide diuretics.

Neurohormonal prognostic markers

  • B-type natriuretic peptide and NT-proBNP
  • Endothelin-1
  • Miscellaneous (Plasma rennin activity, ANP, NE, hsCRP, calitonin gene related peptide, prostaglandins, erythropoietin…)[3][4][5][6]

References

  1. Tago WH, Francis GS, Morrow DA, et al. National Academy of Clinical Biochemistry Laboratory Medicine. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation. 2007; 116:e90-e109.
  2. 2.0 2.1 Van der Meer P. and Van Veldhuisen DJ. Anaemia and renal dysfunction in chronic heart failure. Heart. 2009; 95: 1808-1812.
  3. Haddad F. et al. Right Ventricular function in Cardiovascular Disease, Part II: Pathophysiology, Clinical Importance and Management of Right Ventricular failure. Circulation. 2008;117:1717-1731
  4. Maeder M, Fehr T, Rickli H, Ammann P. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest. 2006;129:1349 –1366.
  5. Pousset F, Isnard R, Lecnat R et al. Prognostic value of plasma endothelin-1 in patients with chroninc heart failure. Eur Heart J. 1997; 18:254-258.
  6. Hobbs RE. Using BNP to diagnose, manage, and treat heart failure. Cleve Clin J Med 2003;70:333–6.